On April 20, Shanghai Kehua Bio-Engineering Co.Ltd(002022) ( Shanghai Kehua Bio-Engineering Co.Ltd(002022) , Shanghai Kehua Bio-Engineering Co.Ltd(002022) ) released the 2021 annual performance express and the risk warning announcement that the company’s shares may be delisted.
The announcement said that the company’s subsidiaries Xi’an Tianlong Technology Co., Ltd. and Suzhou Tianlong Biotechnology Co., Ltd. (hereinafter collectively referred to as “Tianlong company”) refused to cooperate with the audit of the company’s 2021 annual report, which may lead to the issuance of an audit report with “unable to express opinions” in the company’s 2021 annual financial report. The company’s shares may be subject to delisting risk warning.
Shanghai Kehua Bio-Engineering Co.Ltd(002022) said that as of the disclosure date of this announcement, the senior managers of Tianlong company headed by general manager Li Ming violated the company’s regulations on the management rules and regulations of its holding subsidiaries and the articles of association of Tianlong company, and refused to implement the resolutions made by the board of directors of Tianlong company, Refusing to cooperate with Lixin Certified Public Accountants (special general partnership) (hereinafter referred to as “Lixin certified public accountants”) engaged by the company to carry out the audit work in 2021, and refusing to provide important information such as the financial books of Tianlong company in 2021, which may lead to the audit report of “unable to express an opinion” issued by Lixin certified public accountants.
According to the announcement, Shanghai Kehua Bio-Engineering Co.Ltd(002022) as the controlling shareholder of Tianlong company, will continue to actively exercise the management rights of the listed company over its holding subsidiaries, urge and require Tianlong company and its directors, senior managers, financial departments and relevant parties to strictly perform their respective duties and obligations, fulfill their duties, ensure the integrity and safety of the property of the listed company and Tianlong company, and ensure the integrity and authenticity of financial vouchers.
Shanghai Kehua Bio-Engineering Co.Ltd(002022) said that the company will take all legal and necessary measures, including seeking judicial relief through civil, administrative, criminal and other legal channels, for the acts of some directors, senior managers, relevant persons in charge of the financial department and other relevant parties of Tianlong company in violation of the rules of the securities market and the requirements of the company’s standardized operation, as well as the relevant persons responsible for the losses caused to the listed company and all shareholders, Investigate the legal responsibilities of relevant responsible persons, and resolutely safeguard the legitimate rights and interests of the company and shareholders, especially small and medium-sized shareholders.
The announcement also disclosed the performance express of 2021, with an operating revenue of about 4.469 billion yuan, an increase of 7.55% year-on-year (compared with the same period of the previous year); The net profit attributable to shareholders of listed companies was about 721 million yuan, an increase of 6.76% year-on-year Shanghai Kehua Bio-Engineering Co.Ltd(002022) also pointed out that the financial data of 2021 contained in this announcement is only preliminary accounting data, which has not been approved by the accounting firm, and may be different from the final data disclosed in the annual report. Investors are reminded to pay attention to investment risks.
As early as December 27 last year, Shanghai Kehua Bio-Engineering Co.Ltd(002022) announced that the company had received the audit response letter from Li Ming, director and general manager of Xi’an Tianlong Technology Co., Ltd. and Suzhou Tianlong Biotechnology Co., Ltd. (collectively referred to as “Tianlong company”), the holding subsidiaries. In the letter, Tianlong company made it clear that it was unable to cooperate with Shanghai Kehua Bio-Engineering Co.Ltd(002022) pre-trial accounting statements and subsequent audit work. The reason given by Tianlong company is that there is an investment dispute between Shanghai Kehua Bio-Engineering Co.Ltd(002022) and Peng niancai and other arbitration applicants, and the court has ruled to prohibit Shanghai Kehua Bio-Engineering Co.Ltd(002022) from exercising all shareholders’ rights of 62% equity of Xi’an Tianlong and opening financial information to Shanghai Kehua Bio-Engineering Co.Ltd(002022) and there is a risk of trade secret disclosure.
On January 18 this year, Shanghai Kehua Bio-Engineering Co.Ltd(002022) replied to the letter of concern of Shenzhen Stock Exchange, saying that it could not be ruled out that the company had lost control of Xi’an Tianlong Technology Co., Ltd. and Suzhou Tianlong Biotechnology Co., Ltd. (collectively referred to as “Tianlong company”). At present, the company legally holds 62% of the equity of Tianlong company, is still the legal controlling shareholder of Tianlong company, occupies a majority in its board of directors, and has the right to approve and make decisions on major matters. On the other hand, the minority shareholders of Tianlong company have made it clear that Tianlong company is unable to cooperate with Shanghai Kehua Bio-Engineering Co.Ltd(002022) pre-trial accounting statements and subsequent audit work, indicating that the company has difficulties in actively leading the operation and financial activities of Tianlong company. If the control over Tianlong company is lost, it will have a significant impact on the performance of the company’s consolidated financial statements.
Earlier, on June 11, 2018, Shanghai Kehua Bio-Engineering Co.Ltd(002022) announced that the company signed the investment agreement with Tianlong company and the existing shareholders of Tianlong company, agreeing to invest 554 million yuan in cash to obtain 62% equity of Xi’an Tianlong and Suzhou Tianlong respectively.
According to the announcement of Shanghai Kehua Bio-Engineering Co.Ltd(002022)
According to the official website, Shanghai Kehua Bio-Engineering Co.Ltd(002022) headquartered in Shanghai, founded in 1981 and listed on the small and medium-sized board of Shenzhen Stock Exchange in 2004, is an in vitro diagnosis company integrating R & D, production and sales, with rich production experience and a complete echelon of medical diagnosis products . The AIDS diagnostic reagents developed by the company have been certified by WHO (WHO) PQ, and have been included in the purchasing catalogue by several organizations and countries such as the United Nations Children’s Fund (UNICEF) and the United States Agency for International Development (USAID).
As of the closing on April 20, Shanghai Kehua Bio-Engineering Co.Ltd(002022) reported 12.99 yuan, down 1.67%.
